Kore Private Wealth’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Kore Private Wealth’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500	Closed	-$12K	–	1188
2020 Q2	$12K	Hold	500	–	–	﹤0.01%	762
2020 Q1	$9K	Hold	500	–	–	﹤0.01%	714
2019 Q4	$11K	Buy	+500	New	+$10.1K	﹤0.01%	733
2019 Q2	–	Sell	-500	Closed	-$7K	–	847
2019 Q1	$7K	Hold	500	–	–	﹤0.01%	727
2018 Q4	$5K	Buy	+500	New	+$6.58K	﹤0.01%	702

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Kore Private Wealth's DRNA Position: Q3 2020 in Review

Kore Private Wealth sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 500 shares — an estimated $12K sold.

Kore Private Wealth first reported a position in DRNA in Q4 2018 and held it in 5 quarters. The position peaked at $12K in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

Kore Private Wealth reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Kore Private Wealth sold 500 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $12K.
Kore Private Wealth first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Kore Private Wealth's Dicerna Pharmaceuticals, Inc. position peaked at $12K in Q2 2020.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.